SpringerLink
Log in

Rituximab/COVID-19-vaccine Gamaleya National Research Center of Epidemiology and Microbiology

Hemiplegia, ataxia and poor immunisation: case report

  • Case report
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Etemadifar M, et al. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient. Human Vaccines and Immunotherapeutics 17: 3481-3483, No. 10, 3 Oct 2021. Available from: URL: http://doi.org/10.1080/21645515.2021.1928463

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rituximab/COVID-19-vaccine Gamaleya National Research Center of Epidemiology and Microbiology. Reactions Weekly 1878, 467 (2021). https://doi.org/10.1007/s40278-021-04437-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-04437-z

Search

Navigation